Hadidchi emphasizes that oral GLP-1 therapy should be considered only after a thorough medical evaluation and in conjunction with lifestyle modification
Enhanced Energy Utilization: Improved insulin sensitivity allows the body to use glucose more efficiently for energy, contributing to reduced fat storage
They are not intended for human or veterinary use, medical advice, dosing, administration, treatment, or promised outcomes
Peptide Sensitivity: Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist
Semaglutide generally has a more favorable safety profile, primarily causing gastrointestinal side effects
A one-percentage-point reduction in HbA1c typically equates to a 40% reduction in the risk of diabetic complications like vision loss, heart disease, stroke, kidney failure, amputation, and premature death